Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication

被引:27
作者
Dummer, R
Döbbeling, U
Geertsen, R
Willers, J
Burg, G
Pavlovic, J
机构
[1] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland
[2] Univ Zurich, Dept Virol, CH-8006 Zurich, Switzerland
关键词
D O I
10.1182/blood.V97.2.523
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cutaneous T-cell lymphomas (CTCL) comprise a heterogeneous group of lymphoproliferative disorders that are characterized by an accumulation of T-lymphocytes in the skin and occasionally In blood known as Sezary syndrome (SS), In most cases the dominant clone displays T-helper 2 cytokines, Because IFN-gamma is a natural inhibitor of T-helper 2 cells and IFN-alpha is frequently used in CTCL, the impact of IFNs on SS-derived purified clonal T-helper 2 cells was studied using anti-v beta antibodies. Moreover, IFNs are known to mediate virus resistance in normal cells. The isolated clonal CD4(+) cells, but not the nonclonal CD4+ cells, appeared resistant to IfN-gamma and IFN-alpha stimulation in terms of human leukocyte antigen up-regulation and MxA induction caused in part by alterations in Stat-1 molecule mRNA and IFN gamma R1 mRNA transcription. The IFN resistance of the patient-derived clonal cells was then targeted by vesicular stomatitis virus infection after IFN-alpha priming, resulting in selective viral replication in clonal cells. In contrast, nonclonal cells of the same patient showed IFN-dependent MxA expression, which is a major mediator protein of viral protection. The IFN resistance of the dominant T-helper 2 cells might be important for lymphomagenesis, Interferon signaling deficiencies can be targeted for purging patients' cells in vitro. Furthermore, this approach may allow specific molecular interventions, resulting in the efficient treatment of CTCL and other IFN-resistant neoplasms such as lung cancer. (C) 2001 by The American Society of Hematology.
引用
收藏
页码:523 / 527
页数:5
相关论文
共 44 条
[1]   MYCOSIS-FUNGOIDES - CLINICAL AND HISTOLOGIC FEATURES, STAGING, EVALUATION, AND APPROACH TO TREATMENT [J].
ABEL, EA ;
WOOD, GS ;
HOPPE, RT .
CA-A CANCER JOURNAL FOR CLINICIANS, 1993, 43 (02) :93-115
[2]  
ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
[3]   LIGAND-INDUCED AUTOREGULATION OF IFN-GAMMA RECEPTOR-BETA CHAIN EXPRESSION IN T-HELPER CELL SUBSETS [J].
BACH, EA ;
SZABO, SJ ;
DIGHE, AS ;
ASHKENAZI, A ;
AGUET, M ;
MURPHY, KM ;
SCHREIBER, RD .
SCIENCE, 1995, 270 (5239) :1215-1218
[4]   The IFN gamma receptor: A paradigm for cytokine receptor signaling [J].
Bach, EA ;
Aguet, M ;
Schreiber, RD .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :563-&
[5]   MUTUALLY EXCLUSIVE INTERACTION OF THE CCAAT-BINDING FACTOR AND OF A DISPLACEMENT PROTEIN WITH OVERLAPPING SEQUENCES OF A HISTONE GENE PROMOTER [J].
BARBERIS, A ;
SUPERTIFURGA, G ;
BUSSLINGER, M .
CELL, 1987, 50 (03) :347-359
[6]  
Bigler RD, 1996, AM J PATHOL, V149, P1477
[7]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[8]  
Bogen SA, 1996, AM J CLIN PATHOL, V106, P739
[9]   PRE-SEZARY ERYTHRODERMA EVOLVING TO SEZARY SYNDROME - A REPORT OF 7 CASES [J].
BUECHNER, SA ;
WINKELMANN, RK .
ARCHIVES OF DERMATOLOGY, 1983, 119 (04) :285-291
[10]  
BUNN PA, 1979, CANCER TREAT REP, V63, P725